Medication info

Tralitin Combi Tablet 2.5/850mg

Prescription medicationTabletOralExpired
Ingredient · strength
Linagliptin›2.5mg / 1 tabletMetformin Hydrochloride›850mg / 1 tablet
Manufacturer / importer
Daewon Pharmaceutical Co., Ltd.
Appearance
Bright orange, double-convex, oval film-coated tablets
Packaging
60 tablets (10 tablets/PTP X 6)
Approval status
Expired

MFDS item code 201904183 · Approved 2019.06.14

This product's status changed to Expired on 2024.06.14. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine should be administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior history of antidiabetic drug treatment whose blood glucose is not adequately controlled with monotherapy, the initial dose is 1 tablet of this medicine 2.5/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 2.5/1000 mg twice daily. 2. Patients whose blood glucose is not adequately controlled with metformin monotherapy: The initial dose of this medicine should contain linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and the patient's previous metformin dose (e.g., patients taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should start at their previous doses of linagliptin and metformin. 4. Patients whose blood glucose is not adequately controlled with combination therapy with metformin and a sulfonylurea: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and a dose similar to the patient's previous metformin dose. When this medicine is administered in combination with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Administration with Caution in the Following Patients). 5. Patients whose blood glucose is not adequately controlled with combination therapy with insulin and metformin: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and a dose similar to the patient's previous metformin dose. When this medicine is administered in combination with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Administration with Caution in the Following Patients). Patients with renal impairment In patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate [eGFR] 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, this medicine may be used with the following dose adjustments. Treatment should not be initiated with this medicine, because the starting dose of metformin is 500mg or 850mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine must be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 1. Do Not Administer to the Following Patients).

Ingredients

Manufacturer
Daewon Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication is used to assist patients with type 2 diabetes in controlling their blood glucose levels by using a combination of linagliptin and metformin. When administered along with dietary and exercise therapies, it effectively aids in blood glucose management and helps to maintain stable blood sugar levels for patients. This can reduce the risk of complications associated with diabetes. Consistent usage is important for safe and effective treatment. This medication improves blood glucose control.

How to take

Adult dose

The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine should be administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior history of antidiabetic drug treatment whose blood glucose is not adequately controlled with monotherapy, the initial dose is 1 tablet of this medicine 2.5/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 2.5/1000 mg twice daily. 2. Patients whose blood glucose is not adequately controlled with metformin monotherapy: The initial dose of this medicine should contain linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and the patient's previous metformin dose (e.g., patients taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should start at their previous doses of linagliptin and metformin. 4. Patients whose blood glucose is not adequately controlled with combination therapy with metformin and a sulfonylurea: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and a dose similar to the patient's previous metformin dose. When this medicine is administered in combination with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Administration with Caution in the Following Patients). 5. Patients whose blood glucose is not adequately controlled with combination therapy with insulin and metformin: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and a dose similar to the patient's previous metformin dose. When this medicine is administered in combination with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Administration with Caution in the Following Patients). Patients with renal impairment In patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate [eGFR] 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, this medicine may be used with the following dose adjustments. Treatment should not be initiated with this medicine, because the starting dose of metformin is 500mg or 850mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine must be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 1. Do Not Administer to the Following Patients).

Precautions

This medication contains two ingredients, metformin and linagliptin, which help control blood sugar levels. However, it can cause serious side effects like lactic acidosis, so it should not be used in patients with poor kidney function, liver issues, acute cardiac problems, or heart failure. Additionally, pregnant or breastfeeding women should not take this medication. Due to the risk of hypoglycemia, blood glucose should be carefully monitored when taken alongside insulin or sulfonylurea medications. This medication is sensitive to kidney function, and caution is particularly necessary in elderly individuals with reduced kidney function or in patients taking other drugs that may impact kidney performance. There may also be rare side effects like acute pancreatitis or blistering dermatitis, so if unusual symptoms occur, one should consult a doctor immediately. Moreover, due to the metformin component, vitamin B12 levels may decrease, so regular blood tests to monitor vitamin status are recommended. Alcohol consumption should be avoided during treatment, particularly since acute alcohol intoxication increases the risk of lactic acidosis. If iodine contrast agents used in radiological examinations are administered, this medication should be discontinued for a certain period before and after the test, and use should be resumed only after re-evaluating kidney function. This medication has not been adequately studied for safety and efficacy in children or adolescents, therefore it is not recommended for use in these age groups. In case of overdose, serious lactic acidosis can occur, so strict adherence to the prescribed dosage is necessary, and one should visit a medical institution if any unusual symptoms arise. Finally, this medication should be stored in a place away from moisture and out of reach of children, and it is advisable not to transfer it to another container.

Side effects

  • Lactic acidosis
  • nasopharyngitis
  • hypersensitivity
  • angioedema
  • urticaria
  • decreased and deficiency of vitamin B12
  • hypoglycemia
  • taste disorder
  • cough
  • decreased appetite
Show 144 more
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
  • vomiting
  • abdominal pain
  • oral ulcer formation
  • abnormal liver function tests
  • hepatitis
  • pruritus
  • erythema
  • rash
  • pemphigus-like lesions
  • severe and disabling arthralgia
  • rhabdomyolysis
  • increased lipase
  • increased amylase
  • constipation
  • abdominal pain
  • enterocolitis
  • bowel obstruction
  • gastritis
  • herpes zoster
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuritis
  • sepsis
  • pneumonia
  • decreased appetite
  • dehydration
  • hyperglycemia
  • cerebral infarction
  • stuttering
  • Alzheimer's type dementia
  • chest pain
  • fever
  • facial swelling
  • fatigue
  • chronic obstructive pulmonary disease
  • asthma
  • diabetic foot disease
  • skin lesions
  • liver metastasis
  • acute leukemia
  • basal cell carcinoma
  • non-small cell lung cancer
  • malignant pericardial effusion
  • stomach cancer
  • rectal cancer
  • pancreatic cancer
  • meniscus injury
  • pneumoconiosis
  • congestive heart failure
  • angina pectoris
  • acute myocardial infarction
  • unstable angina
  • cardiac arrest
  • diabetic retinopathy
  • acute kidney injury
  • end-stage renal disease
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • dizziness
  • kidney transplant failure
  • anxiety
  • mood disorder
  • insomnia
  • depression
  • contusion
  • bone contusion
  • concussion
  • bone fracture
  • laceration
  • palpitations
  • dry eyes
  • glaucoma
  • cataract
  • ocular discomfort
  • allergic conjunctivitis
  • polyuria
  • proteinuria
  • stress urinary incontinence
  • hematuria
  • hypotension
  • flushing
  • fatty liver disease
  • cholelithiasis
  • hearing loss
  • erectile dysfunction
  • thyroid goiter
  • anemia
  • dizziness
  • sensory loss
  • drowsiness
  • chest discomfort
  • asthenia
  • pain
  • epistaxis
  • oropharyngeal pain
  • voice disorder
  • nasal bleeding
  • runny nose
  • lung mass
  • male pattern baldness
  • hyperhidrosis
  • dermatitis
  • anxiety
  • delirium
  • nocturia
  • pruritus
  • hypertension
  • benign prostatic hyperplasia
  • angina pectoris
  • acute myocardial infarction
  • unstable angina
  • diarrhea
  • stomatitis
  • mediastinitis
  • vitreous hemorrhage
  • fever
  • ligament sprain
  • flank pain
  • myelodysplastic syndrome
  • vocal cord polyp
  • dyspepsia
  • anal bleeding
  • cheilitis
  • dental caries
  • enteritis
  • gastritis
  • gingivitis
  • increased serum creatinine
  • facial swelling
  • back pain
  • osteoarthritis
  • limb pain
  • subdural effusion
  • voice disorder
  • dyslipidemia
  • hypercholesterolemia
  • thyroid nodule
  • dermatitis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, so it must be stored in a tightly sealed container. Additionally, it is best kept at room temperature between 1 and 30 degrees Celsius. This will help maintain the effectiveness of the medication over time.

Appearance and packaging

Appearance

Bright orange, double-convex, oval film-coated tablets

Package unit

60 tablets (10 tablets/PTP X 6)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.